Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491743 |
US |
66 | 2 |
Malignant neoplasm progression, Therapy non-responder, Therapeutic product effect incomplete, Thyroiditis, Off label use, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, CARBOPLATIN, BEVACIZUMAB, |
||||
| 2 | 25492209 |
DE |
86 | 2 |
Immune-mediated myocarditis, Immune-mediated myositis, Malignant neoplasm progression, Coronary artery stenosis, Neck pain, Myalgia, Pneumonia cytomegaloviral, |
||||
NIVOLUMAB, BISOPROLOL FUMARATE, APIXABAN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, TORSEMIDE, LETROZOLE, LETROZOLE TABLETS, |
||||
| 3 | 25492318 |
FR |
59 | 1 |
Malignant neoplasm progression, Skin lesion, Bone marrow failure, Febrile neutropenia, |
||||
| 4 | 25492518 |
US |
63 | 2 |
Malignant neoplasm progression, Off label use, Drug ineffective, |
||||
ABEMACICLIB, |
||||
| 5 | 25493523 |
DE |
2 | |
Metastases to bone, Breast cancer metastatic, Malignant neoplasm progression, |
||||
FULVESTRANT, ZOLEDRONIC ACID, RIBOCICLIB, |
||||
| 6 | 25493595 |
DE |
80 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, PIK3CA-activated mutation, |
||||
FULVESTRANT, ALPELISIB, ALPELISIB, DENOSUMAB, |
||||
| 7 | 25493692 |
BG |
75 | 1 |
Malignant neoplasm progression, Hormone-refractory prostate cancer, |
||||
ENZALUTAMIDE, LEUPROLIDE ACETATE, BICALUTAMIDE, |
||||
| 8 | 25493994 |
DE |
80 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, PIK3CA-activated mutation, |
||||
FULVESTRANT, ALPELISIB, DENOSUMAB, |
||||
| 9 | 25494029 |
JP |
8 | 1 |
Malignant neoplasm progression, Eastern Cooperative Oncology Group performance status worsened, Immune-mediated myelitis, Activities of daily living decreased, |
||||
IPILIMUMAB, NIVOLUMAB, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 10 | 25494104 |
DE |
61 | 1 |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, RITUXIMAB, |
||||
| 11 | 25494194 |
US |
52 | 2 |
Malignant neoplasm progression, Platelet count decreased, |
||||
LORLATINIB, |
||||
| 12 | 25494479 |
CN |
42 | 2 |
Malignant neoplasm progression, Product use in unapproved indication, Brain oedema, |
||||
TEMOZOLOMIDE, BEVACIZUMAB, |
||||
| 13 | 25494689 |
IT |
1 | |
Malignant neoplasm progression, Dehydration, Diarrhoea, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 14 | 25494876 |
US |
86 | 2 |
Bone cancer, Malignant neoplasm progression, Off label use, |
||||
ENCORAFENIB, |
||||
| 15 | 25495092 |
BR |
||
Malignant neoplasm progression, Disease complication, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 16 | 25495165 |
US |
76 | |
Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 17 | 25495273 |
80 | 1 | |
Drug ineffective, Malignant neoplasm progression, |
||||
CAPECITABINE, |
||||
| 18 | 25495455 |
US |
49 | 2 |
Breast cancer female, Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 19 | 25495471 |
JP |
54 | 2 |
Malignant neoplasm progression, Pneumonia, Immune-mediated encephalitis, Fall, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 20 | 25495484 |
JP |
5 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 21 | 25496027 |
PA |
64 | 2 |
Breast cancer, Malignant neoplasm progression, Breast discomfort, Rash vesicular, Skin discolouration, Dry skin, Blister rupture, Pruritus, Pruritus, Hypersensitivity, Rash, Drug ineffective, |
||||
FULVESTRANT, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 22 | 25496208 |
US |
||
Seizure, Malignant neoplasm progression, |
||||
VORASIDENIB, |
||||
| 23 | 25496541 |
CA |
68 | 2 |
Ovarian cancer, Malignant neoplasm progression, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 24 | 25491299 |
JP |
2 | |
Malignant neoplasm progression, Type 1 diabetes mellitus, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 25 | 25491641 |
JP |
44 | 1 |
Immune-mediated mucositis, Therapy partial responder, Malignant neoplasm progression, Penile erosion, Rash erythematous, Hypophagia, Toxic epidermal necrolysis, |
||||
PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, PACLITAXEL, CETUXIMAB, |
||||
| 26 | 25490039 |
FR |
65 | 2 |
Malignant neoplasm progression, Urinary tract infection staphylococcal, Hypokalaemia, Cystitis klebsiella, Decreased appetite, Pyrexia, Nausea, Dysgeusia, |
||||
CARBOPLATIN, PACLITAXEL, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 27 | 25486722 |
TN |
68 | 2 |
Malignant neoplasm progression, |
||||
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, RITUXIMAB, |
||||
| 28 | 25486740 |
BG |
63 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, ZOLEDRONIC ACID, BICALUTAMIDE, |
||||
| 29 | 25486898 |
JP |
53 | 2 |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, PACLITAXEL, CARBOPLATIN, BEVACIZUMAB, |
||||
| 30 | 25487396 |
JP |
74 | |
Metastases to peritoneum, Duodenal stenosis, Lung neoplasm malignant, General physical health deterioration, Malignant neoplasm progression, Deep vein thrombosis, Pulmonary artery thrombosis, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, |
||||
| 31 | 25487510 |
BR |
55 | 1 |
Malignant neoplasm progression, Off label use, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, METHADONE, METHADONE, ENALAPRIL, |
||||
| 32 | 25487934 |
JP |
71 | 2 |
Death, Malignant neoplasm progression, Immune-mediated hepatic disorder, Fracture, Diarrhoea, |
||||
PEMBROLIZUMAB, |
||||
| 33 | 25488578 |
DE |
2 | |
Breast cancer, Metastases to bone, Malignant neoplasm progression, Pneumonia, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 34 | 25488630 |
CN |
||
Metastases to breast, Malignant neoplasm progression, |
||||
GOSERELIN, GOSERELIN, BICALUTAMIDE, ZOLEDRONIC ACID, |
||||
| 35 | 25488824 |
CA |
56 | 1 |
Malignant neoplasm progression, |
||||
OXALIPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 36 | 25489074 |
VN |
46 | 2 |
Metastases to lymph nodes, Breast cancer, Malignant neoplasm progression, Metastases to spine, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, FULVESTRANT, RIBOCICLIB, |
||||
| 37 | 25489700 |
JP |
76 | 1 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, |
||||
| 38 | 25490006 |
JP |
64 | 1 |
Malignant neoplasm progression, Drug eruption, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 39 | 25490475 |
US |
70 | 2 |
Malignant neoplasm progression, |
||||
ABEMACICLIB, |
||||
| 40 | 25490703 |
CN |
2 | |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 41 | 25481919 |
TH |
46 | 1 |
Cholangiocarcinoma, Therapy partial responder, Anastomotic ulcer, Colitis, Malignant neoplasm progression, Pancreaticobiliary carcinoma, Computerised tomogram thorax abnormal, Magnetic resonance imaging abnormal, Biliary dilatation, |
||||
PEMBROLIZUMAB, PITAVASTATIN CALCIUM, PITAVASTATIN, CARVEDILOL, |
||||
| 42 | 25482792 |
AU |
80 | 2 |
Malignant neoplasm progression, |
||||
NIRAPARIB, |
||||
| 43 | 25483054 |
US |
||
Pancreatic carcinoma, Malignant neoplasm progression, Off label use, |
||||
CRIZOTINIB, |
||||
| 44 | 25483066 |
JP |
6 | 2 |
Malignant neoplasm progression, Ascites, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, |
||||
| 45 | 25483330 |
US |
66 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 46 | 25483336 |
US |
86 | 2 |
Neoplasm malignant, Malignant neoplasm progression, |
||||
PALBOCICLIB, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 47 | 25483538 |
JP |
7 | 1 |
Malignant neoplasm progression, Erythema multiforme, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 48 | 25483813 |
PT |
67 | 1 |
Obstruction, Malignant neoplasm progression, Onycholysis, Ocular toxicity, Therapy partial responder, Antisynthetase syndrome, |
||||
PACLITAXEL, PEMBROLIZUMAB, CISPLATIN, ERDAFITINIB, ENFORTUMAB VEDOTIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 49 | 25483902 |
IT |
55 | 2 |
Malignant neoplasm progression, Peripheral T-cell lymphoma unspecified recurrent, Arthralgia, Rash, Paraesthesia, Mucosal inflammation, |
||||
GEMCITABINE HYDROCHLORIDE, BUSULFAN, FLUDARABINE PHOSPHATE, DUVELISIB, THIOTEPA, |
||||
| 50 | 25483909 |
US |
66 | 2 |
Acute promyelocytic leukaemia, Malignant neoplasm progression, Hidradenitis, Necrosis, |
||||
CYTARABINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, |
||||
| 51 | 25483993 |
FR |
80 | 2 |
Malignant neoplasm progression, Hyperthyroidism, |
||||
DOSTARLIMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 52 | 25485217 |
US |
94 | 1 |
Malignant neoplasm progression, Off label use, |
||||
LENALIDOMIDE, ATORVASTATIN CALCIUM, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FINASTERIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, RITUXIMAB-ABBS, ACETAMINOPHEN, SPIRONOLACTONE, FERROUS SULFATE, TAMSULOSIN HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, |
||||
| 53 | 25485319 |
DE |
50 | 1 |
Haemoptysis, Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 54 | 25485470 |
US |
1 | |
Thyroid cancer, Malignant neoplasm progression, |
||||
TRAMETINIB, DABRAFENIB, |
||||
| 55 | 25485603 |
RU |
1 | |
Metastatic malignant melanoma, Malignant neoplasm progression, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 56 | 25485611 |
US |
34 | 2 |
Malignant neoplasm progression, |
||||
BOSUTINIB, |
||||
| 57 | 25486118 |
DE |
||
Toxicity to various agents, Malignant neoplasm progression, Off label use, Drug ineffective, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 58 | 25476069 |
FR |
82 | 1 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 59 | 25476600 |
DE |
55 | 1 |
Malignant neoplasm progression, Radiation necrosis, |
||||
NIVOLUMAB, |
||||
| 60 | 25476965 |
AT |
||
Malignant neoplasm progression, Metastases to liver, Metastases to lung, Drug ineffective, |
||||
CAPIVASERTIB, |
||||
| 61 | 25478091 |
JP |
62 | 2 |
Malignant neoplasm progression, Pneumothorax, Hypothyroidism, Palmar-plantar erythrodysaesthesia syndrome, Fatigue, Hypertension, Stomatitis, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 62 | 25478726 |
CA |
61 | 1 |
Malignant neoplasm progression, Off label use, |
||||
LENALIDOMIDE, |
||||
| 63 | 25478989 |
CZ |
2 | |
Nephrotic syndrome, Ascites, Generalised oedema, Effusion, Proteinuria, Focal segmental glomerulosclerosis, Malignant melanoma, Malignant neoplasm progression, Metastases to central nervous system, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, CITALOPRAM, CITALOPRAM HYDROBROMIDE, DENOSUMAB, |
||||
| 64 | 25479180 |
DE |
61 | 1 |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, |
||||
| 65 | 25479428 |
US |
1 | |
Malignant neoplasm progression, Off label use, Drug ineffective, Product complaint, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 66 | 25480069 |
JP |
72 | 1 |
Epilepsy, Hypomagnesaemia, Malignant neoplasm progression, Hypokalaemia, |
||||
NECITUMUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, |
||||
| 67 | 25480080 |
HR |
56 | 2 |
Neutropenia, Pulmonary mass, Metastases to bone, Metastases to lung, Breast cancer, Malignant neoplasm progression, Spinal pain, |
||||
RIBOCICLIB, RIBOCICLIB, FULVESTRANT, |
||||
| 68 | 25480174 |
FR |
||
Malignant neoplasm progression, Keratitis, Fatigue, Eye pain, Visual impairment, Abdominal pain, Gastrointestinal toxicity, Nausea, Diarrhoea, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 69 | 25480329 |
US |
67 | 1 |
Neuropathy peripheral, Metastases to liver, Malignant neoplasm progression, Rash, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 70 | 25480615 |
US |
2 | |
Toxicity to various agents, Circulating tumour DNA test, Malignant neoplasm progression, |
||||
ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, DENOSUMAB, |
||||
| 71 | 25481086 |
CA |
1 | |
Malignant neoplasm progression, Gastrointestinal neuroendocrine tumour, |
||||
OCTREOTIDE ACETATE, |
||||
| 72 | 25470814 |
US |
64 | 1 |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CARVEDILOL, |
||||
| 73 | 25471138 |
JP |
||
Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, EPCORITAMAB-BYSP, |
||||
| 74 | 25471221 |
PT |
41 | 2 |
Malignant neoplasm progression, Pneumonectomy, Radiotherapy, Myelosuppression, |
||||
CARBOPLATIN, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, DOCETAXEL, DOCETAXEL ANHYDROUS, PEMBROLIZUMAB, ETOPOSIDE, |
||||
| 75 | 25472246 |
RU |
2 | |
Haematotoxicity, Neutropenia, Malignant neoplasm progression, Breast cancer metastatic, |
||||
RIBOCICLIB, ZOLEDRONIC ACID, ANASTROZOLE, ANASTROZOLE TABLETS, GOSERELIN, |
||||
| 76 | 25472468 |
JP |
||
Serous retinal detachment, Malignant melanoma, Malignant neoplasm progression, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, |
||||
| 77 | 25472668 |
DE |
50 | |
Proctitis, Colitis, Hepatitis, Thyroiditis, Post procedural complication, Vitiligo, Malignant neoplasm progression, Metastases to adrenals, |
||||
IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 78 | 25472948 |
VN |
29 | 2 |
Neutropenia, Metastases to lung, Thrombocytopenia, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, Atelectasis, Dyspnoea, Pleural effusion, Drug ineffective, |
||||
CARBOPLATIN, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, DOXORUBICIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GOSERELIN, GOSERELIN, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, PACLITAXEL, RIBOCICLIB, RIBOCICLIB, |
||||
| 79 | 25473134 |
CN |
48 | |
Malignant neoplasm progression, Ureteral neoplasm, Acquired gene mutation, |
||||
GEFITINIB, OSIMERTINIB, |
||||
| 80 | 25473337 |
CL |
64 | 1 |
Hepatitis, Clear cell renal cell carcinoma, Malignant neoplasm progression, Metastases to lung, Hepatic cyst, Off label use, Off label use, |
||||
AXITINIB, SUNITINIB MALATE, SUNITINIB MALATE, SUNITINIB MALATE, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 81 | 25473354 |
US |
47 | 2 |
Bladder cancer, Metastases to peritoneum, Malignant neoplasm progression, Venous thrombosis, Epistaxis, Off label use, |
||||
OXALIPLATIN, OXALIPLATIN, |
||||
| 82 | 25474310 |
74 | 1 | |
Gastrointestinal inflammation, Malignant neoplasm progression, Haemorrhage, |
||||
NIVOLUMAB, CABOZANTINIB, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PROCHLORPERAZINE, OXYBUTYNIN CHLORIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, LOSARTAN, FINASTERIDE, RIVAROXABAN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, MELATONIN, ACETAMINOPHEN AND CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PREDNISONE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, UREA, LEVOTHYROXINE SODIUM, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, FAMOTIDINE, MELATONIN, MICAFUNGIN, MICAFUNGIN SODIUM, TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, FENTANYL, LINEZOLID, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, CEFDINIR, METRONIDAZOLE, METRONIDAZOLE TOPICAL, ENOXAPARIN SODIUM, FLUCONAZOLE, MIRTAZAPINE, DIPHENHYDRAMINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 83 | 25475190 |
DE |
74 | |
Malignant neoplasm progression, Malignant pleural effusion, Metastases to lymph nodes, Acquired gene mutation, Drug resistance, Diarrhoea, Dry skin, Dermatitis acneiform, Fatigue, Hypertension, Dry mouth, Blood creatinine increased, |
||||
OSIMERTINIB, |
||||
| 84 | 25475393 |
US |
47 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Neutropenia, |
||||
PALBOCICLIB, |
||||
| 85 | 25475694 |
IT |
64 | 1 |
Enteritis, Malignant neoplasm progression, |
||||
LENALIDOMIDE, ACYCLOVIR, SULFAMETHOXAZOLE AND TRIMETHOPRIM, |
||||
| 86 | 25475702 |
JP |
||
Bone marrow failure, Neuroendocrine tumour, Malignant neoplasm progression, Physical deconditioning, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 87 | 25465386 |
CN |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 88 | 25465719 |
DE |
61 | 1 |
Malignant neoplasm progression, |
||||
RITUXIMAB, LENALIDOMIDE, |
||||
| 89 | 25465787 |
JP |
60 | 1 |
Death, Neuroendocrine tumour of the rectum, Malignant neoplasm progression, Anaemia, Platelet count decreased, |
||||
LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, |
||||
| 90 | 25466142 |
BE |
||
Malignant neoplasm progression, Off label use, |
||||
OLAPARIB, |
||||
| 91 | 25466179 |
JP |
76 | 1 |
Malignant neoplasm progression, Hepatic function abnormal, General physical health deterioration, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 92 | 25466253 |
DE |
80 | |
Breast cancer metastatic, Malignant neoplasm progression, PIK3CA-activated mutation, |
||||
FULVESTRANT, FULVESTRANT, ALPELISIB, ALPELISIB, DENOSUMAB, |
||||
| 93 | 25466311 |
AU |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 94 | 25466321 |
ES |
43 | 2 |
Breast cancer metastatic, Metastases to bone, Malignant neoplasm progression, Mastectomy, Metastases to lymph nodes, Axillary lymphadenectomy, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOXORUBICIN, ZOLEDRONIC ACID, GOSERELIN, |
||||
| 95 | 25466825 |
AU |
1 | |
Central nervous system neoplasm, Philadelphia chromosome positive, Malignant neoplasm progression, B-cell type acute leukaemia, |
||||
IMATINIB, IMATINIB, DASATINIB, DASATINIB, |
||||
| 96 | 25467595 |
US |
42 | 1 |
Vomiting, Hypovolaemic shock, Clostridium difficile infection, Colitis ulcerative, Malignant neoplasm progression, Blood thyroid stimulating hormone abnormal, Diarrhoea, Weight decreased, |
||||
NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 97 | 25467761 |
US |
||
Bell^s palsy, Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 98 | 25468256 |
CN |
33 | 1 |
Leukopenia, Metastases to central nervous system, Hydrothorax, Ascites, Metastases to peritoneum, Lymphangiosis carcinomatosa, Metastases to bone, Metastases to lymph nodes, Metastases to muscle, Pulmonary embolism, Pericardial effusion, Seizure, Malignant neoplasm progression, Fatigue, Vomiting, Anaemia, Liver function test abnormal, C-reactive protein increased, Blood creatinine increased, |
||||
GEMCITABINE HYDROCHLORIDE, PACLITAXEL, |
||||
| 99 | 25468458 |
RU |
2 | |
Haematotoxicity, Neutropenia, Breast cancer metastatic, Malignant neoplasm progression, |
||||
RIBOCICLIB, ZOLEDRONIC ACID, ANASTROZOLE, ANASTROZOLE TABLETS, GOSERELIN, |
||||
| 100 | 25468587 |
CA |
73 | 2 |
Dysphagia, Malignant neoplasm progression, Neoplasm malignant, Breast cancer metastatic, Burn oesophageal, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, CAPECITABINE, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29